Rezultati pretraživanja
  1. 2. velj

    Watching for tomorrow:

    1 korisnik označava da mu se sviđa
  2. 1. velj

    Head to Head Review: Idera Pharmaceuticals and CytRx

  3. 29. sij

    Looking worse than ever. -2.26 % change recently

  4. 29. sij

    50 DMA Resistance today: ...

  5. 29. sij

    Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

  6. 28. sij

    2020-01-27 Short sale volume (not short interest) for is 59%. 43% 14% 36%

  7. 28. sij

    Idera Pharmaceuticals Inc Sees Significant Decrease in Short Interest

  8. 27. sij

    : New SEC Filing for IDRA: Form 8-K (No. 0001104659-20-007208):

  9. 27. sij

    - Current Report Filing (8-k)

  10. 27. sij

    Thus far in an ongoing P1/2, Tilsotolimod plus Ipilimumab have bested Ipilimumab alone (historically) in anti-PD-1 refractory metastatic melanoma: 24% ORR vs 4-16% and 71% DCR vs 17-45%. mOS is not yet mature ranging between 1.6-35 months. Only 49 evaluable patients.

    Prikaži ovu nit
    Prikaži ovu nit
  11. 27. sij

    Mgnt foresees a "pivotal year" with registrational P3 results due around year end 2020. Along the way we'll a couple of earlier stage readouts that will give us a clue regarding P3 success. Cash good into 1Q21.

    1 reply
    Prikaži ovu nit
    Prikaži ovu nit
  12. 27. sij

    Fell Below 50 DMA today: ...

  13. 21. sij

    Losers-3 -12% -12% -12% -11% -11% -11% -11% -11%

    1 korisnik označava da mu se sviđa
  14. 21. sij

    Watching long term with good dividend penny stock about to explode 👊🏻👊🏻

    2 korisnika označavaju da im se sviđa
  15. 19. sij

    Will TLR9 agonism have its day? And, if so, will tilso be the one to get it done? My thoughts:

    1 reply 1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  16. 19. sij

    breaking out ahead of multiple catalysts. ILLUMINATE-301 enrollment completion Q1 (pivotal data likely Q4), final data ILLUMINATE 204 in Q2, Initial safety & ORR data MSS CRC cohort in Q2 (tilso + ipi + nivo)- thanks Larry for the heads up🙏

    1 reply 2 proslijeđena tweeta 5 korisnika označava da im se sviđa
  17. 15. sij

    ka jalwa 🔥 Khud to roz trending me aata hai Sath me dusre logo ko footage dekar trend karwa deta 😎❤️ bhi trend kar rha~~

    5 replies 69 proslijeđenih tweetova 123 korisnika označavaju da im se sviđa
  18. 15. sij

    Biotech updates 01/14: -ve Adcom -15% AH lower 4Q revenues -30% cystinosis data -30% 1:55 reverse split Parkinson's +29% Pipeline updates

    1 reply 5 proslijeđenih tweetova 16 korisnika označava da im se sviđa
  19. 5. sij

    SELLAS Life Sciences Group In Acquisition Discussions With Janssen Oncology As Johnson & Johnson Increase Their Breast Cancer Portfolio

    4 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
  20. 23. pro 2019.

    1️⃣2️⃣Biggest Market Gainers

    6 korisnika označava da im se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.